Then the log-rank test analysis indicated that patients with high expression of SLC11A1 in the Chinese Glioma Genome Atlas (CGGA), TCGA, Rembrandt and GSE16011 cohorts presented markedly poorer prognoses than those with low expression of SLC11A1 (Figures 2A–D), while a similar but nonsignificant trend was observed in patients derived from the GSE4412 and GSE43289 cohorts (Figures 2E, F). Here, SLC11A1 is linked to central nervous system cancer.